BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Schonmann Y, Yeshua H, Bentov I, Zelber-Sagi S. Liver fibrosis marker is an independent predictor of cardiovascular morbidity and mortality in the general population. Dig Liver Dis. 2021;53:79-85. [PMID: 33144054 DOI: 10.1016/j.dld.2020.10.014] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
Number Citing Articles
1 Weinstein G, O'Donnell A, Davis-Plourde K, Zelber-Sagi S, Ghosh S, DeCarli CS, Thibault EG, Sperling RA, Johnson KA, Beiser AS, Seshadri S. Non-Alcoholic Fatty Liver Disease, Liver Fibrosis, and Regional Amyloid-β and Tau Pathology in Middle-Aged Adults: The Framingham Study. J Alzheimers Dis 2022. [PMID: 35213373 DOI: 10.3233/JAD-215409] [Reference Citation Analysis]
2 Liu M, Mei K, Tan Z, Huang S, Liu F, Deng C, Ma J, Yu P, Liu X, Marasco G. Liver Fibrosis Scores and Hospitalization, Mechanical Ventilation, Severity, and Death in Patients with COVID-19: A Systematic Review and Dose-Response Meta-Analysis. Canadian Journal of Gastroenterology and Hepatology 2022;2022:1-11. [DOI: 10.1155/2022/7235860] [Reference Citation Analysis]
3 Syed T, Siddiqui MS. Atherogenic Dyslipidemia After Liver Transplantation: Mechanisms and Clinical Implications. Liver Transpl 2021;27:1326-33. [PMID: 33837670 DOI: 10.1002/lt.26069] [Reference Citation Analysis]
4 Ballestri S, Mantovani A, Baldelli E, Lugari S, Maurantonio M, Nascimbeni F, Marrazzo A, Romagnoli D, Targher G, Lonardo A. Liver Fibrosis Biomarkers Accurately Exclude Advanced Fibrosis and Are Associated with Higher Cardiovascular Risk Scores in Patients with NAFLD or Viral Chronic Liver Disease. Diagnostics (Basel) 2021;11:98. [PMID: 33435415 DOI: 10.3390/diagnostics11010098] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 13.0] [Reference Citation Analysis]
5 Zhang J, Liu F, Song T, Li Z, Xia P, Tang X, Xu M, Shen Y, Ma J, Liu X, Yu P. Liver Fibrosis Scores and Clinical Outcomes in Patients With COVID-19. Front Med 2022;9:829423. [DOI: 10.3389/fmed.2022.829423] [Reference Citation Analysis]
6 Angelico F, Baratta F, Pastori D, Del Ben M. Assessment of hepatic fibrosis in MAFLD: A new player in the evaluation of residual cardiovascular risk? Digestive and Liver Disease 2021;53:383-4. [DOI: 10.1016/j.dld.2020.12.123] [Cited by in Crossref: 3] [Article Influence: 3.0] [Reference Citation Analysis]
7 Martínez-Urbistondo D, de la Garza RG, Villares-Fernández P, Font C, Schellong S, López-Núñez JJ, Gil-Díaz A, Del Carmen Díaz-Pedroche M, Hirmerova J, Monreal M; RIETE Investigators. Liver status and outcomes in patients without previous known liver disease receiving anticoagulant therapy for venous thromboembolism. Intern Emerg Med 2021. [PMID: 34626318 DOI: 10.1007/s11739-021-02858-x] [Reference Citation Analysis]
8 Yu X, Chen C, Guo Y, Tong Y, Zhao Y, Wu L, Sun X, Wu X, Song Z. High NAFLD fibrosis score in non-alcoholic fatty liver disease as a predictor of carotid plaque development: a retrospective cohort study based on regular health check-up data in China. Ann Med 2021;53:1621-31. [PMID: 34498502 DOI: 10.1080/07853890.2021.1974081] [Reference Citation Analysis]
9 Ashraf H, Karbalai S, Jamali R. Nonalcoholic fatty liver disease and cardiovascular concerns: The time for hepatologist and cardiologist close collaboration. WJMA 2021;9:163-74. [DOI: 10.13105/wjma.v9.i2.163] [Reference Citation Analysis]
10 Kim SW, Jeon JH, Moon JS, Kim MK. High Fibrosis-4 Index Is Related with Worse Clinical Outcome in Patients with Coronavirus Disease 2019 and Diabetes Mellitus: A Multicenter Observational Study. Endocrinol Metab (Seoul) 2021;36:800-9. [PMID: 34418914 DOI: 10.3803/EnM.2021.1040] [Reference Citation Analysis]
11 Higuchi M, Tamaki N, Kurosaki M, Inada K, Kirino S, Yamashita K, Hayakawa Y, Osawa L, Takaura K, Maeyashiki C, Kaneko S, Yasui Y, Takahashi Y, Tsuchiya K, Nakanishi H, Itakura J, Loomba R, Enomoto N, Izumi N. Longitudinal association of magnetic resonance elastography-associated liver stiffness with complications and mortality. Aliment Pharmacol Ther 2021. [PMID: 34927277 DOI: 10.1111/apt.16745] [Reference Citation Analysis]
12 Kawashima A, Yamamoto Y, Sato M, Nakata W, Kakuta Y, Ishizuya Y, Yamaguchi Y, Yamamoto A, Yoshida T, Takayama H, Takada T, Inoue H, Okuda Y, Kato T, Hatano K, Uemura M, Nonomura N, Imamura R. FAN score comprising fibrosis-4 index, albumin-bilirubin score and neutrophil-lymphocyte ratio is a prognostic marker of urothelial carcinoma patients treated with pembrolizumab. Sci Rep 2021;11:21199. [PMID: 34707147 DOI: 10.1038/s41598-021-00509-x] [Reference Citation Analysis]
13 Castellana M, Donghia R, Guerra V, Procino F, Castellana F, Zupo R, Lampignano L, Sardone R, De Pergola G, Romanelli F, Trimboli P, Giannelli G. Fibrosis-4 Index vs Nonalcoholic Fatty Liver Disease Fibrosis Score in Identifying Advanced Fibrosis in Subjects With Nonalcoholic Fatty Liver Disease: A Meta-Analysis. Am J Gastroenterol 2021;116:1833-41. [PMID: 34160377 DOI: 10.14309/ajg.0000000000001337] [Reference Citation Analysis]
14 Ashraf H, Karbalai S, Jamali R. Nonalcoholic fatty liver disease and cardiovascular concerns: The time for hepatologist and cardiologist close collaboration. World J Meta-Anal 2021; 9(2): 164-175 [DOI: 10.13105/wjma.v9.i2.164] [Reference Citation Analysis]
15 Mo M, Huang Z, Liang Y, Liao Y, Xia N. The safety and efficacy evaluation of Sodium-Glucose co-transporter 2 inhibitors for patients with non-alcoholic fatty Liver disease: An updated meta-analysis. Dig Liver Dis 2021:S1590-8658(21)00733-7. [PMID: 34507895 DOI: 10.1016/j.dld.2021.08.017] [Reference Citation Analysis]
16 Perdomo CM, Garcia-Fernandez N, Escalada J. Diabetic Kidney Disease, Cardiovascular Disease and Non-Alcoholic Fatty Liver Disease: A New Triumvirate? J Clin Med 2021;10:2040. [PMID: 34068699 DOI: 10.3390/jcm10092040] [Reference Citation Analysis]